Toby C. Campbell, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Toby C. Campbell, MD is a member of the University of Wisconsin Carbone Cancer Center as an associate professor of medicine within the hematology-oncology section of the UW School of Medicine and Public Health as well as chief of the Palliative Care program and program director of the Palliative Care fellowship training program. Dr. Campbell received his medical degree from the University of Virginia and completed his internal medicine residency at the University of Wisconsin Hospital and Clinics. He recently completed fellowships in medical oncology and palliative medicine at Northwestern University.
Dr. Campbell's clinical practice interests are in Lung Cancer, symptom management, communication and Palliative Care. His clinical research interests are in lung cancer therapeutics, chemotherapy-induced peripheral neuropathy, symptom management, and interdisciplinary medical teams. He is a member of the American Society of Clinical Oncology, American Association of Hospice and Palliative Medicine and the American Association for the Physician and Patient.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
Hospice and Palliative Medicine
University of Wisconsin Hospital and Clinics, Madison, WI
University of Virginia School of Medicine, Charlottesville, VA, 2001
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Programs & Conditions
Dr. Campbell is part of the Lung Disease-Oriented Working Group, through which multiple clinical trials in lung cancer are helping to find better treatments for those with cancer. His research interest is lung cancer therapeutics, including early phase clinical trials, and the management of chemotherapy-induced peripheral neuropathy.
Callander N Markovina S Eickhoff J Hutson P Campbell T Hematti P Go R Hegeman R Longo W Williams E Asimakopoulos F Miyamoto S .
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct;74(4):875-82
[PubMed ID: 25168296]
Kruser TJ McCabe BP Mehta MP Khuntia D Campbell TC Geye HM Cannon GM .
Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol. 2014 Feb;37(1):70-6
[PubMed ID: 23357968]
Hoang T Campbell TC Zhang C Kim K Kolesar JM Oettel KR Blank JH Robinson EG Ahuja HG Kirschling RJ Johnson PH Huie MS Wims ME Larson MM Hernan HR Traynor AM .
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs. 2014 Feb;32(1):195-9
[PubMed ID: 23728919]
Schwarze ML Kehler JM Campbell TC .
Navigating high risk procedures with more than just a street map. J Palliat Med. 2013 Oct;16(10):1169-71
[PubMed ID: 24003993]
Rocque GB Campbell TC Cleary JF .
Reply to A. Azad et al. J Oncol Pract. 2013 Sep;9(5):e273
[PubMed ID: 23943908]
Traynor AM Weigel TL Oettel KR Yang DT Zhang C Kim K Salgia R Iida M Brand TM Hoang T Campbell TC Hernan HR Wheeler DL .
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul;81(1):138-41
[PubMed ID: 23628526]
Gustafson DH DuBenske LL Namkoong K Hawkins R Chih MY Atwood AK Johnson R Bhattacharya A Carmack CL Traynor AM Campbell TC Buss MK Govindan R Schiller JH Cleary JF .
An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial. Cancer. 2013 May 1;119(9):1744-51
[PubMed ID: 23355273]
Rocque GB Barnett AE Illig LC Eickhoff JC Bailey HH Campbell TC Stewart JA Cleary JF .
Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care? J Oncol Pract. 2013 Jan;9(1):51-4
[PubMed ID: 23633971]
Huang TC Campbell TC .
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012 Oct;38(6):613-7
[PubMed ID: 22155063]
O'Mahar SE Campbell TC Hoang T Seo S Kim K Larson MM Marcotte SM LoConte NK Traynor AM .
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 May;6(5):951-3
[PubMed ID: 21623267]
Ledesma W Campbell TC .
A conceptual solution to improve the management of cancer-related breakthrough pain. J Support Oncol. 2010 Nov-Dec;8(6):241
[PubMed ID: 21265390]
Campbell TC Carey EC Jackson VA Saraiya B Yang HB Back AL Arnold RM .
Discussing prognosis: balancing hope and realism. Cancer J. 2010 Sep-Oct;16(5):461-6
[PubMed ID: 20890141]
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G .
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
Campbell TC Roenn JH .
Palliative Care for Interventional Radiology: An Oncologist's Perspective. Semin Intervent Radiol. 2007 Dec;24(4):375-81
[PubMed ID: 21326589]